Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Gabapentin (02255898), PMS-Gabapentin (02255901). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
GABAPENTIN
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (N02BF) — coverage varies; not interchangeable
- Pregabalin (Lyrica): general benefit, Not a benefit
Apo-Gabapentin · DIN 02244304 · 100mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Gabapentin · DIN 02244304
Manufacturer: Apotex Inc.; listing date 2002-07-29
Health Canada: Marketed since 2001-08-27 · brand APO-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Apotex inc · schedule Prescription
Apo-Gabapentin: Formulary list price $0.0416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68271 · Verify on the e-Formulary ↗ (DIN 02244304)
Source record
DIN 02244304: Apo-Gabapentin
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id APX
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.0416; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244304
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68271
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Auro-Gabapentin · DIN 02321203 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02246314 · $0.0416
Gabapentin · DIN 02353245 · $0.0416
Gabapentin Capsules USP · DIN 02416840 · $0.0416
Jamp Gabapentin Capsules · DIN 02535246 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
Mint-Gabapentin · DIN 02408880 · $0.0416
NRA-Gabapentin · DIN 02550016 · $0.0416
Neurontin · DIN 02084260 · $0.0416
PMS-Gabapentin · DIN 02243446 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Teva-Gabapentin · DIN 02244513 · $0.0416
Shortage status: resolved shortage (ended 2026-07-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244304
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Gabapentin · DIN 02321203 · 100mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Gabapentin · DIN 02321203
Manufacturer: Auro Pharma Inc.; listing date 2011-12-15
Health Canada: Marketed since 2011-06-15 · brand AURO-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Auro pharma inc · schedule Prescription
Auro-Gabapentin: Formulary list price $0.0416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80660 · Verify on the e-Formulary ↗ (DIN 02321203)
Source record
DIN 02321203: Auro-Gabapentin
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id AUR
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.0416; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02321203
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80660
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Apo-Gabapentin · DIN 02244304 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02246314 · $0.0416
Gabapentin · DIN 02353245 · $0.0416
Gabapentin Capsules USP · DIN 02416840 · $0.0416
Jamp Gabapentin Capsules · DIN 02535246 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
Mint-Gabapentin · DIN 02408880 · $0.0416
NRA-Gabapentin · DIN 02550016 · $0.0416
Neurontin · DIN 02084260 · $0.0416
PMS-Gabapentin · DIN 02243446 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Teva-Gabapentin · DIN 02244513 · $0.0416
Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02321203
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Gabapentin · DIN 02246314 · 100mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Gabapentin · DIN 02246314
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2009-11-19
Health Canada: Marketed since 2026-09-14 · brand GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Gabapentin: Formulary list price $0.0416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada); extract: Marketed Apr 13, 2018; live record preferred: Marketed Sep 14, 2026 (checked Sep 19, 2026) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70477 · Verify on the e-Formulary ↗ (DIN 02246314)
Source record
DIN 02246314: Gabapentin
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id SIV
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.0416; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246314
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada); extract: Marketed 2018-04-13; live record preferred: Marketed 2026-09-14 (checked 2026-09-19) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70477
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Apo-Gabapentin · DIN 02244304 · $0.0416
Auro-Gabapentin · DIN 02321203 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02353245 · $0.0416
Gabapentin Capsules USP · DIN 02416840 · $0.0416
Jamp Gabapentin Capsules · DIN 02535246 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
Mint-Gabapentin · DIN 02408880 · $0.0416
NRA-Gabapentin · DIN 02550016 · $0.0416
Neurontin · DIN 02084260 · $0.0416
PMS-Gabapentin · DIN 02243446 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Teva-Gabapentin · DIN 02244513 · $0.0416
Shortage status: resolved shortage (ended 2018-04-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246314
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Gabapentin · DIN 02353245 · 100mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Gabapentin · DIN 02353245
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2013-10-10 · brand GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Sanis health inc · schedule Prescription
Gabapentin: Formulary list price $0.0416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83846 · Verify on the e-Formulary ↗ (DIN 02353245)
Source record
DIN 02353245: Gabapentin
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id SAI
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.0416; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02353245
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83846
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Apo-Gabapentin · DIN 02244304 · $0.0416
Auro-Gabapentin · DIN 02321203 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02246314 · $0.0416
Gabapentin Capsules USP · DIN 02416840 · $0.0416
Jamp Gabapentin Capsules · DIN 02535246 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
Mint-Gabapentin · DIN 02408880 · $0.0416
NRA-Gabapentin · DIN 02550016 · $0.0416
Neurontin · DIN 02084260 · $0.0416
PMS-Gabapentin · DIN 02243446 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Teva-Gabapentin · DIN 02244513 · $0.0416
Shortage status: resolved shortage (ended 2026-05-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353245
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Gabapentin Capsules USP · DIN 02416840 · 100mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Gabapentin Capsules USP · DIN 02416840
Manufacturer: Accord Healthcare Inc.; listing date 2015-05-28
Health Canada: Marketed since 2025-11-18 · brand ACH-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Accord healthcare inc · schedule Prescription
Gabapentin Capsules USP: Formulary list price $0.0416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90145 · Verify on the e-Formulary ↗ (DIN 02416840)
Source record
DIN 02416840: Gabapentin Capsules USP
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id ACH
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.0416; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02416840
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90145
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Apo-Gabapentin · DIN 02244304 · $0.0416
Auro-Gabapentin · DIN 02321203 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02246314 · $0.0416
Gabapentin · DIN 02353245 · $0.0416
Jamp Gabapentin Capsules · DIN 02535246 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
Mint-Gabapentin · DIN 02408880 · $0.0416
NRA-Gabapentin · DIN 02550016 · $0.0416
Neurontin · DIN 02084260 · $0.0416
PMS-Gabapentin · DIN 02243446 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Teva-Gabapentin · DIN 02244513 · $0.0416
Shortage status: active shortage (reported 2024-01-19, last updated 2024-01-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416840
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Gabapentin Capsules · DIN 02535246 · 100mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Gabapentin Capsules · DIN 02535246
Manufacturer: Jamp Pharma Corporation; listing date 2024-04-30
Health Canada: Marketed since 2024-03-07 · brand JAMP GABAPENTIN CAPSULES · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Jamp pharma corporation · schedule Prescription
Jamp Gabapentin Capsules: Formulary list price $0.0416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102411 · Verify on the e-Formulary ↗ (DIN 02535246)
Source record
DIN 02535246: Jamp Gabapentin Capsules
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id JPC
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.0416; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02535246
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102411
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Apo-Gabapentin · DIN 02244304 · $0.0416
Auro-Gabapentin · DIN 02321203 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02246314 · $0.0416
Gabapentin · DIN 02353245 · $0.0416
Gabapentin Capsules USP · DIN 02416840 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
Mint-Gabapentin · DIN 02408880 · $0.0416
NRA-Gabapentin · DIN 02550016 · $0.0416
Neurontin · DIN 02084260 · $0.0416
PMS-Gabapentin · DIN 02243446 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Teva-Gabapentin · DIN 02244513 · $0.0416
Shortage status: resolved shortage (ended 2026-03-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02535246
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Gabapentin · DIN 02408880 · 100mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Gabapentin · DIN 02408880
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2023-11-30
Health Canada: Marketed since 2023-08-25 · brand MINT-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Gabapentin: Formulary list price $0.0416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89363 · Verify on the e-Formulary ↗ (DIN 02408880)
Source record
DIN 02408880: Mint-Gabapentin
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id MIN
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.0416; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408880
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89363
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Apo-Gabapentin · DIN 02244304 · $0.0416
Auro-Gabapentin · DIN 02321203 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02246314 · $0.0416
Gabapentin · DIN 02353245 · $0.0416
Gabapentin Capsules USP · DIN 02416840 · $0.0416
Jamp Gabapentin Capsules · DIN 02535246 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
NRA-Gabapentin · DIN 02550016 · $0.0416
Neurontin · DIN 02084260 · $0.0416
PMS-Gabapentin · DIN 02243446 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Teva-Gabapentin · DIN 02244513 · $0.0416
Shortage status: resolved shortage (ended 2026-05-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408880
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Gabapentin · DIN 02550016 · 100mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Gabapentin · DIN 02550016
Manufacturer: Nora Pharma; listing date 2025-07-31
Health Canada: Marketed since 2025-06-02 · brand NRA-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Nora pharma inc · schedule Prescription
NRA-Gabapentin: Formulary list price $0.0416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103883 · Verify on the e-Formulary ↗ (DIN 02550016)
Source record
DIN 02550016: NRA-Gabapentin
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id NRA
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.0416; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550016
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103883
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Apo-Gabapentin · DIN 02244304 · $0.0416
Auro-Gabapentin · DIN 02321203 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02246314 · $0.0416
Gabapentin · DIN 02353245 · $0.0416
Gabapentin Capsules USP · DIN 02416840 · $0.0416
Jamp Gabapentin Capsules · DIN 02535246 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
Mint-Gabapentin · DIN 02408880 · $0.0416
Neurontin · DIN 02084260 · $0.0416
PMS-Gabapentin · DIN 02243446 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Teva-Gabapentin · DIN 02244513 · $0.0416
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550016
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Neurontin · DIN 02084260 · 100mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Neurontin · DIN 02084260
Manufacturer: Upjohn Canada ULC; listing date 1996-10-01
Health Canada: Marketed since 2023-05-05 · brand NEURONTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15944 · Verify on the e-Formulary ↗ (DIN 02084260)
Source record
DIN 02084260: Neurontin
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id UJC
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.5615; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02084260
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15944
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Apo-Gabapentin · DIN 02244304 · $0.0416
Auro-Gabapentin · DIN 02321203 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02246314 · $0.0416
Gabapentin · DIN 02353245 · $0.0416
Gabapentin Capsules USP · DIN 02416840 · $0.0416
Jamp Gabapentin Capsules · DIN 02535246 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
Mint-Gabapentin · DIN 02408880 · $0.0416
NRA-Gabapentin · DIN 02550016 · $0.0416
PMS-Gabapentin · DIN 02243446 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Teva-Gabapentin · DIN 02244513 · $0.0416
Shortage status: resolved shortage (ended 2023-07-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02084260
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Gabapentin · DIN 02243446 · 100mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Gabapentin · DIN 02243446
Manufacturer: Pharmascience Inc.; listing date 2001-10-11
Health Canada: Marketed since 2001-02-23 · brand PMS-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Pharmascience inc · schedule Prescription
PMS-Gabapentin: Formulary list price $0.0416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67356 · Verify on the e-Formulary ↗ (DIN 02243446)
Source record
DIN 02243446: PMS-Gabapentin
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id PMS
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.0416; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243446
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67356
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Apo-Gabapentin · DIN 02244304 · $0.0416
Auro-Gabapentin · DIN 02321203 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02246314 · $0.0416
Gabapentin · DIN 02353245 · $0.0416
Gabapentin Capsules USP · DIN 02416840 · $0.0416
Jamp Gabapentin Capsules · DIN 02535246 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
Mint-Gabapentin · DIN 02408880 · $0.0416
NRA-Gabapentin · DIN 02550016 · $0.0416
Neurontin · DIN 02084260 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Teva-Gabapentin · DIN 02244513 · $0.0416
Shortage status: resolved shortage (ended 2019-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243446
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Gabapentin · DIN 02244513 · 100mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Gabapentin · DIN 02244513
Manufacturer: Teva Canada Limited; listing date 2002-07-29
Health Canada: Marketed since 2010-04-21 · brand TEVA-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 100 MG · company Teva canada limited · schedule Prescription
Teva-Gabapentin: Formulary list price $0.0416/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0416 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68490 · Verify on the e-Formulary ↗ (DIN 02244513)
Source record
DIN 02244513: Teva-Gabapentin
Raw flags: sec3=Y
Item: 281200062; group id 430; item number 1070; lccId None; manufacturer id TEV
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.0416; ministry $0.0416
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244513
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68490
Interchangeable products
AG-Gabapentin · DIN 02477912 · $0.0416
Apo-Gabapentin · DIN 02244304 · $0.0416
Auro-Gabapentin · DIN 02321203 · $0.0416
Co Gabapentin · DIN 02256142 · $0.0416
Gabapentin · DIN 02246314 · $0.0416
Gabapentin · DIN 02353245 · $0.0416
Gabapentin Capsules USP · DIN 02416840 · $0.0416
Jamp Gabapentin Capsules · DIN 02535246 · $0.0416
Jamp-Gabapentin · DIN 02361469 · $0.0416
Mar-Gabapentin · DIN 02391473 · $0.0416
Mint-Gabapentin · DIN 02408880 · $0.0416
NRA-Gabapentin · DIN 02550016 · $0.0416
Neurontin · DIN 02084260 · $0.0416
PMS-Gabapentin · DIN 02243446 · $0.0416
Ran-Gabapentin · DIN 02319055 · $0.0416
Shortage status: resolved shortage (ended 2026-03-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244513
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Gabapentin · DIN 02244305 · 300mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Gabapentin · DIN 02244305
Manufacturer: Apotex Inc.; listing date 2002-07-29
Health Canada: Marketed since 2001-08-27 · brand APO-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Apotex inc · schedule Prescription
Apo-Gabapentin: Formulary list price $0.1012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68273 · Verify on the e-Formulary ↗ (DIN 02244305)
Source record
DIN 02244305: Apo-Gabapentin
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id APX
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1012; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244305
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68273
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Auro-Gabapentin · DIN 02321211 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02246315 · $0.1012
Gabapentin · DIN 02353253 · $0.1012
Gabapentin Capsules USP · DIN 02416859 · $0.1012
Jamp Gabapentin Capsules · DIN 02535254 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
Mint-Gabapentin · DIN 02408899 · $0.1012
NRA-Gabapentin · DIN 02550024 · $0.1012
Neurontin · DIN 02084279 · $0.1012
PMS-Gabapentin · DIN 02243447 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Teva-Gabapentin · DIN 02244514 · $0.1012
Shortage status: resolved shortage (ended 2026-08-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244305
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Gabapentin · DIN 02321211 · 300mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Gabapentin · DIN 02321211
Manufacturer: Auro Pharma Inc.; listing date 2011-12-15
Health Canada: Marketed since 2011-06-15 · brand AURO-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Auro pharma inc · schedule Prescription
Auro-Gabapentin: Formulary list price $0.1012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80661 · Verify on the e-Formulary ↗ (DIN 02321211)
Source record
DIN 02321211: Auro-Gabapentin
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id AUR
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1012; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02321211
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80661
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Apo-Gabapentin · DIN 02244305 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02246315 · $0.1012
Gabapentin · DIN 02353253 · $0.1012
Gabapentin Capsules USP · DIN 02416859 · $0.1012
Jamp Gabapentin Capsules · DIN 02535254 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
Mint-Gabapentin · DIN 02408899 · $0.1012
NRA-Gabapentin · DIN 02550024 · $0.1012
Neurontin · DIN 02084279 · $0.1012
PMS-Gabapentin · DIN 02243447 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Teva-Gabapentin · DIN 02244514 · $0.1012
Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02321211
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Gabapentin · DIN 02246315 · 300mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Gabapentin · DIN 02246315
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2009-11-19
Health Canada: Marketed since 2018-04-13 · brand GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Gabapentin: Formulary list price $0.1012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70478 · Verify on the e-Formulary ↗ (DIN 02246315)
Source record
DIN 02246315: Gabapentin
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id SIV
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1012; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246315
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70478
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Apo-Gabapentin · DIN 02244305 · $0.1012
Auro-Gabapentin · DIN 02321211 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02353253 · $0.1012
Gabapentin Capsules USP · DIN 02416859 · $0.1012
Jamp Gabapentin Capsules · DIN 02535254 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
Mint-Gabapentin · DIN 02408899 · $0.1012
NRA-Gabapentin · DIN 02550024 · $0.1012
Neurontin · DIN 02084279 · $0.1012
PMS-Gabapentin · DIN 02243447 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Teva-Gabapentin · DIN 02244514 · $0.1012
Shortage status: resolved shortage (ended 2018-04-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246315
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Gabapentin · DIN 02353253 · 300mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Gabapentin · DIN 02353253
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2013-10-10 · brand GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Sanis health inc · schedule Prescription
Gabapentin: Formulary list price $0.1012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83847 · Verify on the e-Formulary ↗ (DIN 02353253)
Source record
DIN 02353253: Gabapentin
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id SAI
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1012; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02353253
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83847
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Apo-Gabapentin · DIN 02244305 · $0.1012
Auro-Gabapentin · DIN 02321211 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02246315 · $0.1012
Gabapentin Capsules USP · DIN 02416859 · $0.1012
Jamp Gabapentin Capsules · DIN 02535254 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
Mint-Gabapentin · DIN 02408899 · $0.1012
NRA-Gabapentin · DIN 02550024 · $0.1012
Neurontin · DIN 02084279 · $0.1012
PMS-Gabapentin · DIN 02243447 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Teva-Gabapentin · DIN 02244514 · $0.1012
Shortage status: resolved shortage (ended 2026-04-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353253
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Gabapentin Capsules USP · DIN 02416859 · 300mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Gabapentin Capsules USP · DIN 02416859
Manufacturer: Accord Healthcare Inc.; listing date 2015-05-28
Health Canada: Marketed since 2025-11-18 · brand ACH-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Accord healthcare inc · schedule Prescription
Gabapentin Capsules USP: Formulary list price $0.1012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90146 · Verify on the e-Formulary ↗ (DIN 02416859)
Source record
DIN 02416859: Gabapentin Capsules USP
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id ACH
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1012; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02416859
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90146
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Apo-Gabapentin · DIN 02244305 · $0.1012
Auro-Gabapentin · DIN 02321211 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02246315 · $0.1012
Gabapentin · DIN 02353253 · $0.1012
Jamp Gabapentin Capsules · DIN 02535254 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
Mint-Gabapentin · DIN 02408899 · $0.1012
NRA-Gabapentin · DIN 02550024 · $0.1012
Neurontin · DIN 02084279 · $0.1012
PMS-Gabapentin · DIN 02243447 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Teva-Gabapentin · DIN 02244514 · $0.1012
Shortage status: active shortage (reported 2023-12-29, last updated 2024-01-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416859
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Gabapentin Capsules · DIN 02535254 · 300mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Gabapentin Capsules · DIN 02535254
Manufacturer: Jamp Pharma Corporation; listing date 2024-04-30
Health Canada: Marketed since 2024-03-07 · brand JAMP GABAPENTIN CAPSULES · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Jamp pharma corporation · schedule Prescription
Jamp Gabapentin Capsules: Formulary list price $0.1012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102412 · Verify on the e-Formulary ↗ (DIN 02535254)
Source record
DIN 02535254: Jamp Gabapentin Capsules
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id JPC
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1012; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02535254
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102412
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Apo-Gabapentin · DIN 02244305 · $0.1012
Auro-Gabapentin · DIN 02321211 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02246315 · $0.1012
Gabapentin · DIN 02353253 · $0.1012
Gabapentin Capsules USP · DIN 02416859 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
Mint-Gabapentin · DIN 02408899 · $0.1012
NRA-Gabapentin · DIN 02550024 · $0.1012
Neurontin · DIN 02084279 · $0.1012
PMS-Gabapentin · DIN 02243447 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Teva-Gabapentin · DIN 02244514 · $0.1012
Shortage status: resolved shortage (ended 2026-03-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02535254
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Gabapentin · DIN 02408899 · 300mg · capsule
General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Gabapentin · DIN 02408899
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2023-11-30
Health Canada: Marketed since 2023-08-25 · brand MINT-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Gabapentin: Formulary list price $0.1012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89364 · Verify on the e-Formulary ↗ (DIN 02408899)
Source record
DIN 02408899: Mint-Gabapentin
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id MIN
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1012; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408899
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89364
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Apo-Gabapentin · DIN 02244305 · $0.1012
Auro-Gabapentin · DIN 02321211 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02246315 · $0.1012
Gabapentin · DIN 02353253 · $0.1012
Gabapentin Capsules USP · DIN 02416859 · $0.1012
Jamp Gabapentin Capsules · DIN 02535254 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
NRA-Gabapentin · DIN 02550024 · $0.1012
Neurontin · DIN 02084279 · $0.1012
PMS-Gabapentin · DIN 02243447 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Teva-Gabapentin · DIN 02244514 · $0.1012
Shortage status: resolved shortage (ended 2026-05-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408899
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Gabapentin · DIN 02550024 · 300mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Gabapentin · DIN 02550024
Manufacturer: Nora Pharma; listing date 2025-07-31
Health Canada: Marketed since 2025-06-02 · brand NRA-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Nora pharma inc · schedule Prescription
NRA-Gabapentin: Formulary list price $0.1012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103884 · Verify on the e-Formulary ↗ (DIN 02550024)
Source record
DIN 02550024: NRA-Gabapentin
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id NRA
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1012; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550024
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103884
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Apo-Gabapentin · DIN 02244305 · $0.1012
Auro-Gabapentin · DIN 02321211 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02246315 · $0.1012
Gabapentin · DIN 02353253 · $0.1012
Gabapentin Capsules USP · DIN 02416859 · $0.1012
Jamp Gabapentin Capsules · DIN 02535254 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
Mint-Gabapentin · DIN 02408899 · $0.1012
Neurontin · DIN 02084279 · $0.1012
PMS-Gabapentin · DIN 02243447 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Teva-Gabapentin · DIN 02244514 · $0.1012
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550024
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Neurontin · DIN 02084279 · 300mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Neurontin · DIN 02084279
Manufacturer: Upjohn Canada ULC; listing date 1996-10-01
Health Canada: Marketed since 2023-05-05 · brand NEURONTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15945 · Verify on the e-Formulary ↗ (DIN 02084279)
Source record
DIN 02084279: Neurontin
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id UJC
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $1.3430; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02084279
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15945
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Apo-Gabapentin · DIN 02244305 · $0.1012
Auro-Gabapentin · DIN 02321211 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02246315 · $0.1012
Gabapentin · DIN 02353253 · $0.1012
Gabapentin Capsules USP · DIN 02416859 · $0.1012
Jamp Gabapentin Capsules · DIN 02535254 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
Mint-Gabapentin · DIN 02408899 · $0.1012
NRA-Gabapentin · DIN 02550024 · $0.1012
PMS-Gabapentin · DIN 02243447 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Teva-Gabapentin · DIN 02244514 · $0.1012
Shortage status: resolved shortage (ended 2018-01-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02084279
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Gabapentin · DIN 02243447 · 300mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Gabapentin · DIN 02243447
Manufacturer: Pharmascience Inc.; listing date 2001-10-11
Health Canada: Marketed since 2001-02-23 · brand PMS-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Pharmascience inc · schedule Prescription
PMS-Gabapentin: Formulary list price $0.1012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67357 · Verify on the e-Formulary ↗ (DIN 02243447)
Source record
DIN 02243447: PMS-Gabapentin
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id PMS
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1012; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243447
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67357
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Apo-Gabapentin · DIN 02244305 · $0.1012
Auro-Gabapentin · DIN 02321211 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02246315 · $0.1012
Gabapentin · DIN 02353253 · $0.1012
Gabapentin Capsules USP · DIN 02416859 · $0.1012
Jamp Gabapentin Capsules · DIN 02535254 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
Mint-Gabapentin · DIN 02408899 · $0.1012
NRA-Gabapentin · DIN 02550024 · $0.1012
Neurontin · DIN 02084279 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Teva-Gabapentin · DIN 02244514 · $0.1012
Shortage status: resolved shortage (ended 2019-11-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243447
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Gabapentin · DIN 02244514 · 300mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Gabapentin · DIN 02244514
Manufacturer: Teva Canada Limited; listing date 2002-07-29
Health Canada: Marketed since 2010-04-21 · brand TEVA-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 300 MG · company Teva canada limited · schedule Prescription
Teva-Gabapentin: Formulary list price $0.1012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68491 · Verify on the e-Formulary ↗ (DIN 02244514)
Source record
DIN 02244514: Teva-Gabapentin
Raw flags: sec3=Y
Item: 281200063; group id 430; item number 1071; lccId None; manufacturer id TEV
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1012; ministry $0.1012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244514
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68491
Interchangeable products
AG-Gabapentin · DIN 02477920 · $0.1012
Apo-Gabapentin · DIN 02244305 · $0.1012
Auro-Gabapentin · DIN 02321211 · $0.1012
Co Gabapentin · DIN 02256150 · $0.1012
Gabapentin · DIN 02246315 · $0.1012
Gabapentin · DIN 02353253 · $0.1012
Gabapentin Capsules USP · DIN 02416859 · $0.1012
Jamp Gabapentin Capsules · DIN 02535254 · $0.1012
Jamp-Gabapentin · DIN 02361485 · $0.1012
Mar-Gabapentin · DIN 02391481 · $0.1012
Mint-Gabapentin · DIN 02408899 · $0.1012
NRA-Gabapentin · DIN 02550024 · $0.1012
Neurontin · DIN 02084279 · $0.1012
PMS-Gabapentin · DIN 02243447 · $0.1012
Ran-Gabapentin · DIN 02319063 · $0.1012
Shortage status: resolved shortage (ended 2026-06-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244514
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Gabapentin · DIN 02244306 · 400mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Gabapentin · DIN 02244306
Manufacturer: Apotex Inc.; listing date 2002-07-29
Health Canada: Marketed since 2001-08-27 · brand APO-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 400 MG · company Apotex inc · schedule Prescription
Apo-Gabapentin: Formulary list price $0.1206/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1206 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68274 · Verify on the e-Formulary ↗ (DIN 02244306)
Source record
DIN 02244306: Apo-Gabapentin
Raw flags: sec3=Y
Item: 281200064; group id 430; item number 1072; lccId None; manufacturer id APX
Source form: Cap; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $0.1206; ministry $0.1206
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244306
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68274
Interchangeable products
AG-Gabapentin · DIN 02477939 · $0.1206
Auro-Gabapentin · DIN 02321238 · $0.1206
Co Gabapentin · DIN 02256169 · $0.1206
Gabapentin · DIN 02246316 · $0.1206
Gabapentin · DIN 02353261 · $0.1206
Gabapentin Capsules USP · DIN 02416867 · $0.1206
Jamp Gabapentin Capsules · DIN 02535262 · $0.1206
Jamp-Gabapentin · DIN 02361493 · $0.1206
Mar-Gabapentin · DIN 02391503 · $0.1206
Mint-Gabapentin · DIN 02408902 · $0.1206
NRA-Gabapentin · DIN 02550032 · $0.1206
Neurontin · DIN 02084287 · $0.1206
PMS-Gabapentin · DIN 02243448 · $0.1206
Ran-Gabapentin · DIN 02319071 · $0.1206
Ratio-Gabapentin · DIN 02260905 · $0.1206
Teva-Gabapentin · DIN 02244515 · $0.1206
Shortage status: shortage reported ended 2026-08-13 (report last updated 2026-08-13); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244306
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Gabapentin · DIN 02321238 · 400mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Gabapentin · DIN 02321238
Manufacturer: Auro Pharma Inc.; listing date 2011-12-15
Health Canada: Marketed since 2011-06-15 · brand AURO-GABAPENTIN · ATC N02BF01 GABAPENTIN · form Capsule · route Oral · ingredients GABAPENTIN 400 MG · company Auro pharma inc · schedule Prescription
Auro-Gabapentin: Formulary list price $0.1206/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1206 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80662 · Verify on the e-Formulary ↗ (DIN 02321238)
Source record
DIN 02321238: Auro-Gabapentin
Raw flags: sec3=Y
Item: 281200064; group id 430; item number 1072; lccId None; manufacturer id AUR
Source form: Cap; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $0.1206; ministry $0.1206
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02321238
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80662
Interchangeable products
AG-Gabapentin · DIN 02477939 · $0.1206
Apo-Gabapentin · DIN 02244306 · $0.1206
Co Gabapentin · DIN 02256169 · $0.1206
Gabapentin · DIN 02246316 · $0.1206
Gabapentin · DIN 02353261 · $0.1206
Gabapentin Capsules USP · DIN 02416867 · $0.1206
Jamp Gabapentin Capsules · DIN 02535262 · $0.1206
Jamp-Gabapentin · DIN 02361493 · $0.1206
Mar-Gabapentin · DIN 02391503 · $0.1206
Mint-Gabapentin · DIN 02408902 · $0.1206
NRA-Gabapentin · DIN 02550032 · $0.1206
Neurontin · DIN 02084287 · $0.1206
PMS-Gabapentin · DIN 02243448 · $0.1206
Ran-Gabapentin · DIN 02319071 · $0.1206
Ratio-Gabapentin · DIN 02260905 · $0.1206
Teva-Gabapentin · DIN 02244515 · $0.1206
Shortage status: resolved shortage (ended 2021-02-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02321238
Shortage record checked 2026-09-13T08:10:21.292534+00:00